View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Sep. 30, 2014	Nov. 08, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	Biota Pharmaceuticals, Inc.
Document Type	10-Q
Current Fiscal Year End Date	--06-30
Entity Common Stock, Shares Outstanding		35,100,961
Amendment Flag	false
Entity Central Index Key	0000072444
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Sep. 30, 2014
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Millions	Sep. 30, 2014	Jun. 30, 2014
Current assets
Cash and cash equivalents	$ 57.7	$ 81.7
Contract receivable	16.3	17.8
Short-term investments	1.1
Other accounts receivable	0.5	0.9
Prepaid and other current assets	0.5	0.7
Total current assets	76.1	101.1
Non-current assets:
Long-term investments	18.8	10.0
Deferred tax asset	0.8	0.9
Property and equipment, net	1.6	2.0
Total non-current assets	21.2	12.9
Total assets	97.3	114.0
Current liabilities:
Contract payables and accrued expenses	13.3	18.6
Accounts payable	1.4	2.8
Accrued expenses	3.2	3.4
Accrued severance obligations	0.6	1.2
Deferred tax liability	0.8	0.9
Total current liabilities	19.3	26.9
Non-current liabilities:
Other liabilities, net of current portion	0.1	0.2
Total liabilities	19.4	27.1
Stockholders’ equity:
Common stock, $0.10 par value: 200,000,000 shares authorized; 35,100,961 and 35,100,961 shares issued and outstanding at September 30, 2014 and June 30, 2014, respectively	3.5	3.5
Additional paid-in capital	146.8	146.4
Accumulated other comprehensive income	24.3	26.8
Accumulated deficit	(96.7)	(89.8)
Total stockholders’ equity	77.9	86.9
Total liabilities and stockholders’ equity	$ 97.3	$ 114.0

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2014	Jun. 30, 2014
Common Stock, Par value (in Dollars per share)	$ 0.10	$ 0.10
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares Issued	35,100,961	35,100,961
Common stock, shares outstanding	35,100,961	35,100,961

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Revenue:
Royalty revenue and milestones	$ 0.0	$ 0.0
Revenue from services	0.7	12.2
Other		0.1
Total revenue	0.7	12.3
Operating expense:
Cost of revenue	1.7	10.7
Research and development	4.9	3.0
General and administrative	2.4	2.4
Foreign exchange (gain) loss	(1.3)	0.3
Total operating expense	7.7	16.4
Loss from operations	(7.0)	(4.1)
Non-operating income:
Interest income	0.1	0.1
Loss before tax	(6.9)	(4.0)
Income tax benefit		0.1
Net Income (Loss)	$ (6.9)	$ (3.9)
Basic loss per share (in Dollars per share)	$ (0.20)	$ (0.14)
Diluted loss per share (in Dollars per share)	$ (0.20)	$ (0.14)
Basic weighted-average shares outstanding (in Shares)	35,029,300	28,291,665
Diluted weighted-average shares outstanding (in Shares)	35,029,300	28,291,665
Comprehensive loss:
Exchange differences on translation of foreign operations	$ (2.5)	$ 0.3
Total comprehensive loss	$ (9.4)	$ (3.6)

Condensed Consolidated Statements of Stockholders' Equity (unaudited) - 3 months ended Sep. 30, 2014 - USD ($) $ in Millions	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accumulated Translation Adjustment [Member]	Total
Balances at July 1, 2014 at Jun. 30, 2014	$ 3.5	$ 146.4	$ 0.0	$ (89.8)	$ 26.8	$ 86.9
Balances at July 1, 2014 (in Shares) at Jun. 30, 2014	35,100,961		0			35,100,961
Exchange differences on translation of foreign operations					(2.5)	$ (2.5)
Net loss				(6.9)		(6.9)
Share-based compensation		0.4				0.4
Balances at September 30, 2014 at Sep. 30, 2014	$ 3.5	$ 146.8	$ 0.0	$ (96.7)	$ 24.3	$ 77.9
Balances at September 30, 2014 (in Shares) at Sep. 30, 2014	35,100,961		0			35,100,961

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:
Net loss	$ (6.9)	$ (3.9)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	0.4	0.5
Share-based compensation	0.4	0.3
Change in operating assets and liabilities (net of liabilities acquired):
Accounts receivables	0.6	(2.0)
Prepaid expenses and other current assets	0.2	0.9
Deferred revenue		(0.2)
Accounts payable and accrued expenses	(5.7)	(1.0)
Accrued severance obligations	(0.6)	(0.8)
Net cash used in operating activities	(11.6)	(6.2)
Cash flows from investing activities:
Purchases of short and long-term investments	(9.9)
Purchases of property and equipment		(0.1)
Net cash used in investing activities	(9.9)	(0.1)
Decrease in cash and cash equivalents	(21.5)	(6.3)
Cash and cash equivalents at beginning of period	81.7	66.8
Effects of exchange rate movements on cash and cash equivalents	(2.5)	0.3
Cash and cash equivalents at end of period	$ 57.7	$ 60.8

Note 1 - Company Overview

3 Months Ended

Sep. 30, 2014

Disclosure Text Block [Abstract]

Nature of Operations [Text Block]

(1) Company Overview

Biota Pharmaceuticals, Inc., together with its wholly owned subsidiaries (“Biota”, or the “Company”) is a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening infectious diseases. The Company has been incorporated in the state of Delaware since 1969 and its corporate headquarters are located in Alpharetta, Georgia.

The Company is currently focused on developing oral, small molecule antiviral compounds to treat a number of respiratory-related infections. The most advanced clinical-stage program is laninamivir octanoate, a long-acting neuraminidase inhibitor (“NI”) that the Company has been developing for the treatment of influenza A and B. On August 1, 2014, the Company reported top-line safety and efficacy results from a randomized, double-blind, placebo-controlled, parallel-arm Phase 2 clinical trial comparing the safety and efficacy of a 40 mg and an 80 mg dose of laninamivir octanoate to placebo. As compared to placebo, neither the 40 mg nor the 80 mg cohort achieved a statistically significant reduction in the median time to alleviation of influenza symptoms, the primary endpoint, as measured by the Flu-iiQ patient-recorded outcome questionnaire. Certain important secondary endpoints, including quantitative viral shedding, and secondary bacterial infections, as well as the time to alleviation of influenza symptoms for a number of subcomponents, did achieve statistically significant results for laninamivir octanoate treated cohorts compared to placebo. The Company intends to complete its analyses of the data from this trial and plans to discuss the results of this trial with the U.S. Food and Drug Administration (“FDA”) to determine the appropriate primary endpoint for, and which patient reported outcome tools would be acceptable for use in, any prospective registration trials of laninamivir octanoate to treat uncomplicated influenza.

The Company is also developing BTA-798, also known as vapendavir. Biota has successfully completed two Phase 2 trials of vapendavir to date and recently completed additional Phase 1 bioavailability and drug-drug interaction studies of vapendavir in healthy volunteers. The Company plans to initiate a randomized, double-blind, placebo-controlled dose-ranging Phase 2 trial in moderate and severe asthmatic patients at risk of loss of asthma control due to presumptive human rhinovirus (“HRV”) infection in the first quarter of 2015.

In addition to these Phase 2 clinical-stage development programs, the Company is also developing orally bioavailable F and non-F protein compounds for the treatment of respiratory syncytial virus (“RSV”) infections in children, the elderly and immune-compromised patients. The Company is currently conducting Investigational New Drug application (“IND”) enabling studies with BTA-C585, the lead compound from its F-protein inhibitor program for the treatment of RSV.

In March 2011, the Company was awarded a contract from the U.S. Office of Biomedical Advanced Research and Development Authority (“BARDA”) designed to provide up to $231 million in support of the development of and submission for a New Drug Application (“NDA”) of laninamivir octanoate for the treatment of influenza A and B infections in the United States. On April 23, 2014, the Company was notified by the U.S. Department of Health and Human Services (“HHS”) office of the Assistant Secretary for Preparedness and Response (“ASPR”) and BARDA that pending a decision regarding the outcome of an In-Process Review (“IPR”) of the Company’s contract for the development of laninamivir octanoate, ASPR/BARDA had issued a Stop-Work Order notifying the Company to discontinue work on a number of activities that would no longer be reimbursed under the contract. On May 7, 2014, HHS/ASPR/BARDA notified the Company of its decision to terminate the contract for the convenience of the U.S. Government based upon the results of the IPR. The Company continues to work with ASPR/BARDA to close out this contract, which involves finalizing invoices and billings, determining the nature and extent of any equitable adjustments, and negotiating a final termination settlement.

Although several of the Company’s influenza product candidates have been successfully developed and commercialized to date by other larger pharmaceutical companies under collaboration, license or commercialization agreements, the Company has not independently developed or received regulatory approval for any product candidate, and the Company does not currently have any sales, marketing or commercial capabilities. Therefore, it is possible that the Company may not successfully derive any significant product revenues from any product candidates that it is developing now, or may develop in the future. The Company expects to incur losses for the foreseeable future as it intends to support the clinical and preclinical development of its product candidates. Also, due to the termination of its contract with BARDA, the Company anticipates that its revenue from service and cost of revenue will decline substantially in the future as compared to recent historical levels.

The Company plans to continue to finance its operations with (i) its existing cash, cash equivalents and investments, (ii) proceeds from existing or potential future royalty-bearing licenses or collaborative research and development arrangements, (iii) future equity and/or debt financings, or (iv) other financing arrangements. The Company’s ability to continue to support its operations is dependent, in the near-term, upon managing its cash resources, receiving reimbursements from BARDA related to the close-out of its terminated contract, continuing to receive royalty revenue under existing licenses, entering into future collaboration, license or commercialization agreements, successfully developing its product candidates, executing future financings and ultimately, upon obtaining approval of its products for sale and achieving positive cash flows from operations on a consistent basis. There can be no assurance that additional capital or funds will be available on terms acceptable to the Company, if at all, or that the Company will be able to enter into collaboration, license or commercialization agreements in the future, or that the Company will ever generate significant product revenue and become operationally profitable on a consistent basis.

Note 2 - Basis of Presentation

3 Months Ended

Sep. 30, 2014

Disclosure Text Block [Abstract]

Basis of Presentation and Significant Accounting Policies [Text Block]

(2)

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. All material adjustments considered necessary for a fair presentation have been included. Certain information and footnotes disclosure normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission (“SEC”). Except as disclosed herein, there has been no material change in the information disclosed in the notes to the consolidated financial statements included in the Company’s Annual Report on Form 10-K that was filed with the SEC on September 30, 2014.

The unaudited interim consolidated financial statements include the accounts of the Company and all of its wholly owned subsidiaries. All inter-company transactions and balances are eliminated in consolidation.

Operating results for the three months ended September 30, 2014 are not necessarily indicative of the annual results that may be expected for the Company’s fiscal year ending June 30, 2015. For a more complete discussion of the Company’s significant accounting policies and other information, this report should be read in conjunction with the consolidated financial statements for the fiscal year ended June 30, 2014 included in the Company’s Annual Report on Form 10-K that was filed with the SEC on September 30, 2014.

The Company’s significant accounting policies have not changed since June 30, 2014, except as outlined below:

Recent Accounting Standards

In August 2014, the Financial Accounting Standards Board issued authoritative accounting guidance related to management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Management’s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. This guidance is effective for public and nonpublic entities for annual periods ending after December 15, 2016, and interim periods thereafter. Early adoption is permitted. The Company is currently assessing the expected impact, if any, that this ASU will have on its consolidated financial statements.

In May 2014, the Financial Accounting Standards Board issued authoritative accounting guidance related to revenue from contracts with customers. This guidance is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This guidance is effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. The Company will adopt this guidance on January 1, 2017. Companies may use either a full retrospective or a modified retrospective approach to adopt this guidance. The Company is evaluating which transition approach to use and its impact, if any, on its consolidated financial statements.

Note 3 - Fair Value Measurements

3 Months Ended

Sep. 30, 2014

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

(3)

Fair Value Measurements

A fair value hierarchy has been established which requires the Company to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The fair value hierarchy describes three levels of inputs that may be used to measure fair value:

	Level 1	Quoted prices in active markets for identical assets or liabilities.
	Level 2	Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The following table sets forth the financial assets and liabilities that were measured at fair value on a recurring basis at September 30, 2014 and June 30, 2014, by level within the fair value hierarchy. The assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

The Company’s long-term and short-term investments have been classified as Level 2, which have been initially valued at the transaction price and subsequently revalued, at the end of each reporting period, utilizing a third party pricing service. The pricing service utilizes industry standard valuation models and observable market inputs to determine value that include surveying the bond dealer community, obtaining benchmark quotes, incorporating relevant trade data, and updating spreads daily. There have been no transfers of assets or liabilities between the fair value measurement classifications during the periods presented.

			Quoted Prices in
			Active Markets for		Significant Other		Significant
			Identical Assets		Observable Inputs		Unobservable
	Total		(Level 1)		(Level 2)		Inputs (Level 3)
September 30, 2014
Cash equivalents	$	23.4	$	23.4	$	—	$	—
Short-term investments available-for-sale		1.1		—		1.1		—
Long-term investments available-for-sale		18.8		—		18.8		—

Total	$	43.3	$	23.4	$	19.9	$	—

			Quoted Prices in
			Active Markets for		Significant Other		Significant
			Identical Assets		Observable Inputs		Unobservable
	Total		(Level 1)		(Level 2)		Inputs (Level 3)
June 30, 2014
Cash equivalents	$	36.9	$	36.9	$	—	$	—
Long-term investments available-for-sale		10.0		—		10.0		—

Total	$	46.9	$	36.9	$	10.0		—

Cash equivalents consist primarily of money market funds. Short-term investments consist of corporate securities and have a maturity less than 365 days from the date of acquisition. Long-term investments consist of U.S. agency securities, U.S. Treasury securities, and corporate securities classified as available-for-sale and have maturities greater than 365 days from the date of acquisition.

The Company has had no realized gains or losses from the sale of investments for the twelve months ended September 30, 2014. The following table shows the unrealized gains and losses and fair values for those investments as of September 30, 2014 and June 30, 2014 aggregated by major security type:

			Unrealized		Unrealized
	At Cost		Gains		(Losses)		At Fair Value
September 30, 2014
Money market funds	$	23.4	$	—	$	—	$	23.4
Debt securities of U.S. government agencies		9.4		—		—		9.4
U.S. Treasury securities		7.6		—		—		7.6
Corporate Securities		2.9						2.9

Total	$	43.3	$	—	$	—	$	43.3

			Unrealized		Unrealized
	At Cost		Gains		(Losses)		At Fair Value
June 30, 2014
Money market funds	$	36.9	$	—	$	—	$	36.9
Debt securities of U.S. government agencies		4.9		—		—		4.9
U.S. Treasury securities		5.1		—		—		5.1

Total	$	46.9	$	—	$	—	$	46.9

As of September 30, 2014 and June 30, 2014, the Company had investments in an unrealized loss position. The Company has determined that the unrealized losses of less than $0.1 million on these investments at September 30, 2014 and June 30, 2014 are temporary in nature and expects the securities to mature at their stated maturity principal.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Note 4 - Accrued and Other Current Liabilities

3 Months Ended

Sep. 30, 2014

Disclosure Text Block Supplement [Abstract]

Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]

(4) Accrued and Other Current Liabilities

Accrued and other current liabilities consist of the following (in millions):

	September 30, 2014		June 30, 2014

Professional Fees	$	1.1	$	1.0
Salary and related costs		1.2		0.4
Research and development materials and services		0.8		0.8
Other accrued expenses		0.1		1.2
Total accrued expenses and other liabilities	$	3.2	$	3.4

Note 5 - Net Loss per Share

3 Months Ended

Sep. 30, 2014

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

(5) Net Loss per share

Basic and diluted loss per share has been computed based on net loss and the weighted-average number of common shares outstanding during the applicable period. For diluted net loss per share, common stock equivalents (shares of common stock issuable upon the exercise of stock options and unvested restricted stock units) are excluded from the calculation of diluted net loss per share as their inclusion would be anti-dilutive. The Company has excluded all anti-dilutive share-based awards to purchase common stock in periods indicating a loss, as their effect is anti-dilutive.

The following table sets forth the computation of historical basic and diluted net loss per share.

	Three Months Ended September 30,
	2014			2013

Net loss (in millions)	$	(6.9	)	$	(3.9	)
Weighted-average shares outstanding		35,029,300			28,291,665
Weighted- average shares outstanding adjusted using exchange ratio used to compute basic earnings per share		-			-
Dilutive effect of restricted stock and stock options		-			-
Shares used to compute diluted earnings per share		35,029,300			28,291,665
Basic loss per share	$	(0.20	)	$	(0.14	)
Diluted loss per share	$	(0.20	)	$	(0.14	)
Number of anti-dilutive share-based awards excluded from computation		2,517,636			1,688,529

Note 6 - Licenses, Royalty Collaborative and Contractual Arrangements

3 Months Ended

Sep. 30, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Collaborative Arrangement Disclosure [Text Block]

(6)

Licenses, Royalty Collaborative and Contractual Arrangements

Royalty agreements

The Company entered into a royalty-bearing research and license agreement with GlaxoSmithKline (“GSK”) in 1990 for the development and commercialization of zanamivir, a neuraminidase inhibitor (“NI”) marketed by GSK as Relenza® to treat influenza. Under the terms of the agreement, the Company licensed zanamivir to GSK on an exclusive, worldwide basis and is entitled to receive royalty payments of 7% of GSK's annual net sales of Relenza® in the U.S., Europe, Japan and certain other countries as well as 10% of GSK's annual net sales of Relenza® in Australia, New Zealand, South Africa and Indonesia. The Relenza® patent portfolio is scheduled to expire as follows: December 2014 in the U.S., May 2015 in Australia, 2016 in the major countries of the European Union (EU), and July 2019 in Japan. On August 25, 2014, GSK filed an appeal to the United States Patent Trial Appeal Board in relation to U.S. Patent Application No. 08/737,141. GSK has verified that the Company will continue to receive royalties on the net sales of Relenza® in the United States beyond December 2014 to the extent that this patent application remains pending or is ultimately issued. The Company is unable at this time to determine the duration or the outcome of this appeal process, or how long this patent application will remain pending.

The Company also generates royalty revenue from the sale of laninamivir octanoate, which Daiichi Sankyo markets as Inavir® in Japan, pursuant to a collaboration and license agreement that the Company entered into with Daiichi Sankyo in 2009. In September 2010, laninamivir octanoate was approved for sale by the Japanese Ministry of Health and Welfare for the treatment of influenza in adults and children. Under the agreement, the Company currently receives a 4% royalty on net sales of Inavir® in Japan and is eligible to earn sales milestone payments. Under the collaboration and license agreement, the Company and Daiichi Sankyo have cross-licensed the world-wide rights to develop and commercialize the related intellectual property, and have agreed to share equally in any royalties, license fees, or milestone or other payments received from any third party licenses outside of Japan. Patents on laninamivir octanoate in Japan generally expire in 2024.

Collaborative and contract arrangements

In March 2011, the Company’s wholly owned subsidiary, Biota Scientific Management Pty Ltd., was awarded a contract by BARDA for the late-stage development of laninamivir octanoate on a cost-plus-fixed-fee basis, the total of which is not to exceed $231.2 million. BARDA is part of the U.S. Office of the ASPR within the HHS. The BARDA contract was designed to fund and provide the Company with all technical and clinical data and U.S. based manufacturing to support the filing of a U.S. new drug application (“NDA”) with the FDA for laninamivir octanoate. The performance period of the BARDA contract commenced on March 31, 2011, and was intended to continue for five years. On May 7, 2014 HHS/ASPR/BARDA notified the Company of its decision to terminate the contract for the development of laninamivir octanoate for the convenience of the U.S. Government. The decision to terminate for convenience was the result of a recently concluded IPR. The Company has been and continues to work with ASPR/BARDA to close out this contract, which involves finalizing separate invoices and billings for those activities undertaken prior to and after the termination date, determining the nature and extent of any equitable adjustments for costs incurred after the termination date, and negotiating a final termination settlement. As of September 30, 2014, the Company had $16.3 million in accounts receivable due from BARDA, which does not include $4.9 million of revenue from services and the related accounts receivable that the Company has not recognized for costs that it believes it is entitled to be reimbursed for its terminated contract with BARDA and pursuant to applicable government regulations, but for which it potentially may not be fully reimbursed.

The Company is considered an active participant in the BARDA contract, with exposure to significant risks and rewards of commercialization relating to the development of laninamivir octanoate. Therefore, revenues from and costs associated with the contract are recorded and recognized on a gross basis in the consolidated statement of operations.

The following tables summarize the key components of the Company’s revenues (in millions):

	Three Months Ended September 30,
	2014		2013
	(in millions)
Royalty revenue– Relenza^®	$	-	$	-
– Inavir^®		-		-
Service revenue under BARDA contract		0.7		12.2
Revenue under other contracts, grants and collaborations		-		0.1
Total revenue	$	0.7	$	12.3

Note 7 - Share-based Compensation

3 Months Ended

Sep. 30, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

(7)

Share-based Compensation

For the three months ended September 30, 2014 and 2013, the Company recorded share-based compensation expense related to grants from equity incentive plans of $0.4 million and $0.3 million, respectively. No income tax benefit was recognized in the statements of operations and no share-based compensation expense was capitalized as part of any assets for the three months ended September 30, 2014 and 2013.

Stock Options

The fair value of each stock option award was estimated at its respective date of grant using the Black-Scholes method with the following assumptions:

	Three Months Ended
	September 30,
	2014		2013
Weighted-average risk-free interest rate		1.70		—	%
Dividend yield		—		—
Expected weighted-average volatility		0.82		—
Expected weighted-average life of options (years)		6.0		—
Weighted-average fair value of options granted	$	1.64	$	—

The risk-free interest rate is based on the expected life of the option and the corresponding U.S. Treasury bond, which in most cases is the U.S. five year Treasury bond. The expected term of stock options granted is derived from actual and expected option behavior and represents the period of time that options granted are expected to be outstanding. The Company uses historical data to estimate option exercise patterns and future employee terminations to determine expected life and forfeitures. Expected volatility is based on the historical volatility of the Company’s publicly-traded common stock.

	Number of			Weighted Average Exercise Price		Weighted-Average Remaining Contractual		Aggregate Intrinsic Value
	Stock Options			Per Option		Term		($0000)

Balance at June 30, 2014		2,463,369		$	9.09
Granted		225,000			2.39
Exercised		—			—
Forfeited or expired		(417,904	)		4.38
Balance at September 30, 2014		2,270,465		$	9.30		7.61	$	-

In August 2014, the Company's Board of Directors made a determination that a performance-based milestone was not achieved and as a result, performance-based stock options previously issued during fiscal 2014 will not vest and were cancelled.

The total intrinsic value of stock options exercised during the three month period ended September 30, 2014 was zero, and no cash proceeds were received by the Company. Further, no actual tax benefits were realized, as the Company currently records a full valuation allowance for all tax benefits due to uncertainties with respect to its ability to generate sufficient taxable income in the future.

The following tables summarize information relating to outstanding and exercisable options as of September 30, 2014:

				September 30, 2014
					Outstanding
					Weighted Average					Exercisable
				Number of		Remaining		Weighted Average		Number of		Weighted Average
Exercise Prices				Shares		Contractual Life		Exercise Price		Shares		Exercise Price
						(In Years)
$	2.30	—	$3.98		615,000		9.53	$	2.91		36,250	$	3.84
$	4.05				90,000		8.58		4.05		50,000		4.05
$	4.07				931,590		8.12		4.07		310,531		4.07
$	4.15	—	$93.36		633,875		4.86		23.91		418,875		33.71
					2,270,465		7.61	$	9.30		815,656		19.28

Restricted and Market Stock Units (MSUs). A summary of the Company’s outstanding restricted stock and market stock unit (MSU) activity for the three months ended September 30, 2014 is as follows:

	Shares			Weighted Average Grant Date Fair Value
Outstanding at June 30, 2014		262,072		$	3.98
Awarded		—			—
Released		—			—
Forfeited		(14,901	)		4.06
Unvested at September 30, 2014		247,171		$	3.97

In December 2013, the Company awarded 108,183 MSUs to employees that may vest on January 1, 2017. The vesting of these awards is subject to the respective employee’s continued employment through this settlement period. Further, the number of MSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain market-based criteria involving the Company’s stock price. The number of MSUs actually earned, if any, is calculated upon the vesting of the award. Participants may ultimately earn between 0% and 250% of the target number of units granted based on actual stock performance. Accordingly, additional MSUs may be issued or currently outstanding MSUs may be cancelled upon final determination of the number of awards earned. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.

As of September 30, 2014 there was $3.0 million of unrecognized share-based compensation expense related to all unvested share-based awards, not discounted for future forfeitures. This balance is expected to be recognized over a weighted-average period of two years.

Note 8 - Restructuring Charges

3 Months Ended

Sep. 30, 2014

Restructuring and Related Activities [Abstract]

Restructuring and Related Activities Disclosure [Text Block]

(8)

Restructuring Charges

The Company recognizes restructuring charges when a plan that materially changes the scope of its business or the manner in which that business is conducted is adopted and communicated to the impacted parties, and the expenses have been incurred or are reasonably estimable.

Fiscal 2014 Restructuring Activity

In the fourth quarter of fiscal 2014, the Company announced restructuring actions as a result of the termination of the BARDA contract for the convenience of the U.S. Government. These restructuring activities are expected to be completed in fiscal 2015.

The following is a reconciliation of the beginning and ending balances of the restructuring liability:

	Balance at							Balance at
	June 30,							September 30,
Fiscal 2014 Restructuring Plans:	2014		Provision		Payments			2014
Severance and employment costs		2.0		-		(0.6	)	$	1.4
Total restructuring costs	$	2.0	$	-	$	(0.6	)	$	1.4

The remaining severance and other employment costs of approximately $1.4 million are scheduled to be paid in the second and third quarters of fiscal 2015.

Note 9 - Subsequent Event

3 Months Ended

Sep. 30, 2014

Subsequent Events [Abstract]

Subsequent Events [Text Block]

(9)

Subsequent Event

On November 5, 2014, the Company reached a partial settlement agreement with ASPR and BARDA pursuant to which ASPR/BARDA agreed to reimburse the Company an amount of $4.7 million for all costs associated with the completion of the Phase 2 IGLOO clinical trial of laninamivir octanoate in adults that were incurred after the termination date of the Company’s contract with BARDA.

Accounting Policies, by Policy (Policies)

3 Months Ended

Sep. 30, 2014

Accounting Policies [Abstract]

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Standards

Note 3 - Fair Value Measurements (Tables)

3 Months Ended

Sep. 30, 2014

Fair Value Disclosures [Abstract]

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

			Quoted Prices in
			Active Markets for		Significant Other		Significant
			Identical Assets		Observable Inputs		Unobservable
	Total		(Level 1)		(Level 2)		Inputs (Level 3)
September 30, 2014
Cash equivalents	$	23.4	$	23.4	$	—	$	—
Short-term investments available-for-sale		1.1		—		1.1		—
Long-term investments available-for-sale		18.8		—		18.8		—

Total	$	43.3	$	23.4	$	19.9	$	—

			Quoted Prices in
			Active Markets for		Significant Other		Significant
			Identical Assets		Observable Inputs		Unobservable
	Total		(Level 1)		(Level 2)		Inputs (Level 3)
June 30, 2014
Cash equivalents	$	36.9	$	36.9	$	—	$	—
Long-term investments available-for-sale		10.0		—		10.0		—

Total	$	46.9	$	36.9	$	10.0		—

Unrealized Gain (Loss) on Investments [Table Text Block]

			Unrealized		Unrealized
	At Cost		Gains		(Losses)		At Fair Value
September 30, 2014
Money market funds	$	23.4	$	—	$	—	$	23.4
Debt securities of U.S. government agencies		9.4		—		—		9.4
U.S. Treasury securities		7.6		—		—		7.6
Corporate Securities		2.9						2.9

Total	$	43.3	$	—	$	—	$	43.3

			Unrealized		Unrealized
	At Cost		Gains		(Losses)		At Fair Value
June 30, 2014
Money market funds	$	36.9	$	—	$	—	$	36.9
Debt securities of U.S. government agencies		4.9		—		—		4.9
U.S. Treasury securities		5.1		—		—		5.1

Total	$	46.9	$	—	$	—	$	46.9

Note 4 - Accrued and Other Current Liabilities (Tables)

3 Months Ended

Sep. 30, 2014

Disclosure Text Block Supplement [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

	September 30, 2014		June 30, 2014

Professional Fees	$	1.1	$	1.0
Salary and related costs		1.2		0.4
Research and development materials and services		0.8		0.8
Other accrued expenses		0.1		1.2
Total accrued expenses and other liabilities	$	3.2	$	3.4

Note 5 - Net Loss per Share (Tables)

3 Months Ended

Sep. 30, 2014

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended September 30,
	2014			2013

Net loss (in millions)	$	(6.9	)	$	(3.9	)
Weighted-average shares outstanding		35,029,300			28,291,665
Weighted- average shares outstanding adjusted using exchange ratio used to compute basic earnings per share		-			-
Dilutive effect of restricted stock and stock options		-			-
Shares used to compute diluted earnings per share		35,029,300			28,291,665
Basic loss per share	$	(0.20	)	$	(0.14	)
Diluted loss per share	$	(0.20	)	$	(0.14	)
Number of anti-dilutive share-based awards excluded from computation		2,517,636			1,688,529

Note 6 - Licenses, Royalty Collaborative and Contractual Arrangements (Tables)

3 Months Ended

Sep. 30, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Three Months Ended September 30,
	2014		2013
	(in millions)
Royalty revenue– Relenza^®	$	-	$	-
– Inavir^®		-		-
Service revenue under BARDA contract		0.7		12.2
Revenue under other contracts, grants and collaborations		-		0.1
Total revenue	$	0.7	$	12.3

Note 7 - Share-based Compensation (Tables)

3 Months Ended

Sep. 30, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Three Months Ended
	September 30,
	2014		2013
Weighted-average risk-free interest rate		1.70		—	%
Dividend yield		—		—
Expected weighted-average volatility		0.82		—
Expected weighted-average life of options (years)		6.0		—
Weighted-average fair value of options granted	$	1.64	$	—

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

	Number of			Weighted Average Exercise Price		Weighted-Average Remaining Contractual		Aggregate Intrinsic Value
	Stock Options			Per Option		Term		($0000)

Balance at June 30, 2014		2,463,369		$	9.09
Granted		225,000			2.39
Exercised		—			—
Forfeited or expired		(417,904	)		4.38
Balance at September 30, 2014		2,270,465		$	9.30		7.61	$	-

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]

				September 30, 2014
					Outstanding
					Weighted Average					Exercisable
				Number of		Remaining		Weighted Average		Number of		Weighted Average
Exercise Prices				Shares		Contractual Life		Exercise Price		Shares		Exercise Price
						(In Years)
$	2.30	—	$3.98		615,000		9.53	$	2.91		36,250	$	3.84
$	4.05				90,000		8.58		4.05		50,000		4.05
$	4.07				931,590		8.12		4.07		310,531		4.07
$	4.15	—	$93.36		633,875		4.86		23.91		418,875		33.71
					2,270,465		7.61	$	9.30		815,656		19.28

Schedule of Nonvested Performance-based Units Activity [Table Text Block]

	Shares			Weighted Average Grant Date Fair Value
Outstanding at June 30, 2014		262,072		$	3.98
Awarded		—			—
Released		—			—
Forfeited		(14,901	)		4.06
Unvested at September 30, 2014		247,171		$	3.97

Note 8 - Restructuring Charges (Tables)

3 Months Ended

Sep. 30, 2014

Restructuring and Related Activities [Abstract]

Restructuring and Related Costs [Table Text Block]

	Balance at							Balance at
	June 30,							September 30,
Fiscal 2014 Restructuring Plans:	2014		Provision		Payments			2014
Severance and employment costs		2.0		-		(0.6	)	$	1.4
Total restructuring costs	$	2.0	$	-	$	(0.6	)	$	1.4

Note 1 - Company Overview (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
Note 1 - Company Overview (Details) - USD ($) $ in Millions	Mar. 31, 2011	Sep. 30, 2013
BARDA
Note 1 - Company Overview (Details) [Line Items]
Contracts Revenue	$ 231.0
Contracts Revenue		$ 0.1

Note 3 - Fair Value Measurements (Details) - USD ($)	12 Months Ended
Note 3 - Fair Value Measurements (Details) - USD ($)	Sep. 30, 2014	Jun. 30, 2014
Fair Value Disclosures [Abstract]
Gain (Loss) on Sale of Investments	$ 0
Maximum Unrealized Loss Positions Maturing in Excess of One Year	$ 100,000	$ 100,000

Note 3 - Fair Value Measurements (Details) - Summary of Investments - USD ($) $ in Millions	Sep. 30, 2014	Jun. 30, 2014
Money Market Funds [Member] \| Fair Value, Inputs, Level 1 [Member]
Note 3 - Fair Value Measurements (Details) - Summary of Investments [Line Items]
Short-term investments available-for-sale	$ 23.4	$ 36.9
Money Market Funds [Member]
Note 3 - Fair Value Measurements (Details) - Summary of Investments [Line Items]
Short-term investments available-for-sale	23.4	36.9
Short-term Investments [Member] \| Fair Value, Inputs, Level 2 [Member]
Note 3 - Fair Value Measurements (Details) - Summary of Investments [Line Items]
Short-term investments available-for-sale	1.1
Short-term Investments [Member]
Note 3 - Fair Value Measurements (Details) - Summary of Investments [Line Items]
Short-term investments available-for-sale	1.1
Fair Value, Inputs, Level 1 [Member]
Note 3 - Fair Value Measurements (Details) - Summary of Investments [Line Items]
Total	23.4	36.9
Fair Value, Inputs, Level 2 [Member]
Note 3 - Fair Value Measurements (Details) - Summary of Investments [Line Items]
Long-term investments available-for-sale	18.8	10.0
Total	19.9	10.0
Short-term investments available-for-sale	43.3	46.9
Long-term investments available-for-sale	18.8	10.0
Total	$ 43.3	$ 46.9

- Definition

Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.

+ References + Details

Note 3 - Fair Value Measurements (Details) - Summary of Unrealized Gain (Loss) on Investments - USD ($) $ in Millions	Sep. 30, 2014	Jun. 30, 2014
Money Market Funds [Member]
Note 3 - Fair Value Measurements (Details) - Summary of Unrealized Gain (Loss) on Investments [Line Items]
Investments at Cost	$ 23.4	$ 36.9
Unrealized Gains	0.0	0.0
Unrealized Losses	0.0	0.0
Investments at Fair Value	23.4	36.9
US Government Agencies Debt Securities [Member]
Note 3 - Fair Value Measurements (Details) - Summary of Unrealized Gain (Loss) on Investments [Line Items]
Investments at Cost	9.4	4.9
Unrealized Gains	0.0	0.0
Unrealized Losses	0.0	0.0
Investments at Fair Value	9.4	4.9
US Treasury Securities [Member]
Note 3 - Fair Value Measurements (Details) - Summary of Unrealized Gain (Loss) on Investments [Line Items]
Investments at Cost	7.6	5.1
Unrealized Gains	0.0	0.0
Unrealized Losses	0.0	0.0
Investments at Fair Value	7.6	5.1
Corporate Debt Securities [Member]
Note 3 - Fair Value Measurements (Details) - Summary of Unrealized Gain (Loss) on Investments [Line Items]
Investments at Cost	2.9
Investments at Fair Value	2.9
Investments at Cost	43.3	46.9
Unrealized Gains	0.0	0.0
Unrealized Losses	0.0	0.0
Investments at Fair Value	$ 43.3	$ 46.9

Note 4 - Accrued and Other Current Liabilities (Details) - Summary of Accrued and Other Current Liabilities - USD ($) $ in Millions	Sep. 30, 2014	Jun. 30, 2014
Summary of Accrued and Other Current Liabilities [Abstract]
Professional Fees	$ 1.1	$ 1.0
Salary and related costs	1.2	0.4
Research and development materials and services	0.8	0.8
Other accrued expenses	0.1	1.2
Total accrued expenses and other liabilities	$ 3.2	$ 3.4

Note 5 - Net Loss per Share (Details) - Computation of Historical Basic and Diluted Net Income (Loss) Per Share - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Prior to Adjustments [Member]
Note 5 - Net Loss per Share (Details) - Computation of Historical Basic and Diluted Net Income (Loss) Per Share [Line Items]
Weighted-average shares outstanding	35,029,300	28,291,665
Adjusted Using Exchange Ratio [Member]
Note 5 - Net Loss per Share (Details) - Computation of Historical Basic and Diluted Net Income (Loss) Per Share [Line Items]
Weighted-average shares outstanding	0	0
Basic loss per share (in Dollars per share)	$ (0.20)	$ (0.14)
Diluted loss per share (in Dollars per share)	$ (0.20)	$ (0.14)
Net loss (in millions) (in Dollars)	$ (6.9)	$ (3.9)
Weighted-average shares outstanding	35,029,300	28,291,665
Dilutive effect of restricted stock and stock options	0	0
Shares used to compute diluted earnings per share	35,029,300	28,291,665
Basic loss per share (in Dollars per share)	$ (0.20)	$ (0.14)
Diluted loss per share (in Dollars per share)	$ (0.20)	$ (0.14)
Number of anti-dilutive share-based awards excluded from computation	2,517,636	1,688,529

Note 6 - Licenses, Royalty Collaborative and Contractual Arrangements (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Mar. 31, 2011	Sep. 30, 2014	Jun. 30, 2014
United States, Europe, Japan and Other Countries [Member] \| GSK
Note 6 - Licenses, Royalty Collaborative and Contractual Arrangements (Details) [Line Items]
Royalty Payment Percentage		7.00%
Australia, New Zealand, South Africa and Indonesia \| GSK
Note 6 - Licenses, Royalty Collaborative and Contractual Arrangements (Details) [Line Items]
Royalty Payment Percentage		10.00%
Japan [Member] \| Daiichi Sankyo
Note 6 - Licenses, Royalty Collaborative and Contractual Arrangements (Details) [Line Items]
Royalty Payment Percentage		4.00%
BARDA
Note 6 - Licenses, Royalty Collaborative and Contractual Arrangements (Details) [Line Items]
Maximum Revenue from Contract	$ 231.2
Contract Term	5 years
Contract Receivable		$ 16.3
Contracts Receivable, Claims and Uncertain Amounts		4.9
Contract Receivable		$ 16.3	$ 17.8

Note 6 - Licenses, Royalty Collaborative and Contractual Arrangements (Details) - Components of Revenues from Royalties, Collaborative and Contractual Agreements - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Relenza [Member]
Segment Reporting Information [Line Items]
Royalty revenue	$ 0.0	$ 0.0
Inavir [Member]
Segment Reporting Information [Line Items]
Royalty revenue	0.0	0.0
Royalty revenue	0.0	0.0
Service revenue under BARDA contract	0.7	12.2
Revenue under other contracts, grants and collaborations		0.1
Total revenue	$ 0.7	$ 12.3

Note 7 - Share-based Compensation (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2013
MSU [Member] \| Minimum [Member]
Note 7 - Share-based Compensation (Details) [Line Items]
Percentage of the Target Number of Units Granted Earned Based on Stock Performance		0.00%
MSU [Member] \| Maximum [Member]
Note 7 - Share-based Compensation (Details) [Line Items]
Percentage of the Target Number of Units Granted Earned Based on Stock Performance		250.00%
MSU [Member]
Note 7 - Share-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares)	108,183
The 2007 Omnibus Equity and Incentive Plan [Member]
Note 7 - Share-based Compensation (Details) [Line Items]
Allocated Share-based Compensation Expense		$ 0.3	$ 0.4
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense		0.0	0.0
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount		0.0	$ 0.0
Proceeds from Stock Options Exercised		0.0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		0.0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 3.0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		2 years

Note 7 - Share-based Compensation (Details) - Fair Value Assumptions - $ / shares	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Fair Value Assumptions [Abstract]
Weighted-average risk-free interest rate	1.70%
Dividend yield	0.00%	0.00%
Expected weighted-average volatility	0.82%
Expected weighted-average life of options (years)	6 years
Weighted-average fair value of options granted (in Dollars per share)	$ 1.64

Note 7 - Share-based Compensation (Details) - Stock Option Activity	3 Months Ended
	Sep. 30, 2014 $ / shares shares
Stock Option Activity [Abstract]
Balance at June 30, 2014 \| shares	2,463,369
Balance at June 30, 2014 \| $ / shares	$ 9.09
Granted \| shares	225,000
Granted \| $ / shares	$ 2.39
Forfeited or expired \| shares	(417,904)
Forfeited or expired \| $ / shares	$ 4.38
Balance at September 30, 2014 \| shares	2,270,465
Balance at September 30, 2014 \| $ / shares	$ 9.30
Balance at September 30, 2014	7 years 222 days

Note 7 - Share-based Compensation (Details) - Exercise Price Range Relating to Oustanding and Exercisable Options	3 Months Ended
	Sep. 30, 2014 $ / shares shares
Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Prices Lower Limit	$ 2.30
Exercise Prices Upper Limit	$ 3.98
Outstanding Number of Shares (in Shares) \| shares	615,000
Outstanding Weighted Average Remaining Contractual Life	9 years 193 days
Exercise Price Weighted Average	$ 2.91
Exercisable Number of Shares (in Shares) \| shares	36,250
Exercisable Weighted Average Exercise Price	$ 3.84
Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Prices Lower Limit	$ 4.05
Outstanding Number of Shares (in Shares) \| shares	90,000
Outstanding Weighted Average Remaining Contractual Life	8 years 211 days
Exercise Price Weighted Average	$ 4.05
Exercisable Number of Shares (in Shares) \| shares	50,000
Exercisable Weighted Average Exercise Price	$ 4.05
Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Prices Lower Limit	$ 4.07
Outstanding Number of Shares (in Shares) \| shares	931,590
Outstanding Weighted Average Remaining Contractual Life	8 years 43 days
Exercise Price Weighted Average	$ 4.07
Exercisable Number of Shares (in Shares) \| shares	310,531
Exercisable Weighted Average Exercise Price	$ 4.07
Range Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Prices Lower Limit	4.15
Exercise Prices Upper Limit	$ 93.36
Outstanding Number of Shares (in Shares) \| shares	633,875
Outstanding Weighted Average Remaining Contractual Life	4 years 313 days
Exercise Price Weighted Average	$ 23.91
Exercisable Number of Shares (in Shares) \| shares	418,875
Exercisable Weighted Average Exercise Price	$ 33.71
Outstanding Number of Shares (in Shares) \| shares	2,270,465
Outstanding Weighted Average Remaining Contractual Life	7 years 222 days
Exercise Price Weighted Average	$ 9.30
Exercisable Number of Shares (in Shares) \| shares	815,656
Exercisable Weighted Average Exercise Price	$ 19.28

Note 7 - Share-based Compensation (Details) - Summary of MSU Activity - Restricted Stock and Market Stock Units [Member]	3 Months Ended
	Sep. 30, 2014 $ / shares shares
Note 7 - Share-based Compensation (Details) - Summary of MSU Activity [Line Items]
Unvested Shares \| shares	262,072
Unvested Weighted Average Grant Date Fair Value \| $ / shares	$ 3.98
Awarded \| shares	0
Awarded \| $ / shares	$ 0
Released \| shares	0
Released \| $ / shares	$ 0
Forfeited \| shares	(14,901)
Forfeited \| $ / shares	$ 4.06
Unvested Shares \| shares	247,171
Unvested Weighted Average Grant Date Fair Value \| $ / shares	$ 3.97

Note 8 - Restructuring Charges (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Sep. 30, 2014	Mar. 31, 2015
Scenario, Forecast [Member] \| Employee Severance [Member]
Note 8 - Restructuring Charges (Details) [Line Items]
Restructuring Charges		$ 1.4
Employee Severance [Member]
Note 8 - Restructuring Charges (Details) [Line Items]
Restructuring Charges	$ 0.0
Restructuring Charges	$ 0.0

Note 8 - Restructuring Charges (Details) - Reconciliation of the Beginning and Ending Balances of the Restructuring Liability: $ in Millions	3 Months Ended
	Sep. 30, 2014 USD ($)
Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	$ 0.0
Payments for Restructuring	(0.6)
Restructuring Liability, Ending Balance	1.4
Restructuring Liability, Beginning Balance	2.0
Restructuring Charges	0.0
Payments for Restructuring	(0.6)
Restructuring Liability, Ending Balance	1.4
Restructuring Liability, Beginning Balance	$ 2.0

Note 9 - Subsequent Event (Details) $ in Millions	Nov. 05, 2014 USD ($)
Subsequent Event [Member] \| ASPR and BARDA [Member]
Note 9 - Subsequent Event (Details) [Line Items]
Reimbursement Revenue	$ 4.7